

Product Name: LIMKi 3 Revision Date: 11/27/2023

Product Data Sheet

LIMKi 3

Cat. No.: B7707

CAS No.: 1338247-35-0


Formula: C17H14Cl2F2N4OS

M.Wt: 431.29

Synonyms:

Target: Others
Pathway: Others

Storage: Store at -20°C



Solvent & Solubility

≥44.6 mg/mL in DMSO; ≥6.26 mg/mL in EtOH with ultrasonic; insoluble in H2O

| In Vitro | Preparing Stock Solutions | Solvent Concentration | 1mg | 5mg | 10mg |
|----------|---------------------------|-----------------------|-----------|--------------------------|------------|
| | | 1 mM | 2.3186 mL | 11.5931 mL | 23.1863 mL |
| | | 5 mM | 0.4637 mL | 2.3186 mL | 4.6373 mL |
| | | 10 mM | 0.2319 mL | 1.1 <mark>5</mark> 93 mL | 2.3186 mL |

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

| Shortsummary | LIMK1 and LIMK2 inhibito | or . | |
|---------------------------|--------------------------|--|--|
| IC ₅₀ & Target | | al ^Q norm | |
| | Cell Viability Assay | See The second of the second o | |
| | Cell Line: 1000 0 0000 | Human breast cancer cells MDA-MB-231 | |
| | Preparation method: | The solubility of this compound in DMSO is > 10 mM. General tips for obtaining | |
| In Vitro | | a higher concentration: Please warm the tube at 37°C for 10 minutes and/or | |
| | | shake it in the ultrasonic bath for a while. Stock solution can be stored below | |
| | | -20°C for several months. | |
| | Reacting conditions: | 24 h, 0~10 μM | |

| | Applications: | In MDA-MB-231 cells, LIMKi 3 potently inhibited LIMK activity, the treatment | | |
|------------------|-------------------|--|--|--|
| | | with LIMKi 3 (0~10 μM) resulted in a dose-dependent inhibition of cofilin | | |
| | | phosphorylation, induced a reduction in F-actin signal intensity and | | |
| | Blogger. | serum-stimulated SRF activity. LIMKi 3 had no effect on microtubule number or | | |
| | | organization. 3 μM LIMKi 3 significantly inhibited matrigel invasion in the 3D | | |
| | Expore the | matrigel invasion assay, 0.1~3 μM LIMKi 3 had no effect on wound healing. 10 | | |
| Lines of British | Julea Patestion | μΜ LIMKi 3 significantly reduced the area of gelatin degradation per cell. | | |
| | Egg-tail | Although motility was unaffected, LIMK inhibition by LIMKi 3 impaired matrix | | |
| | | protein degradation. | | |
| In Vivo | Animal experiment | | | |
| | Applications: | | | |

Product Citations

See more customer validations on www.apexbt.com.

References

[1] Scott R W, Hooper S, Crighton D, et al. LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells.[J]. Journal of Cell Biology, 2010, 191(1):169-85.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

2 | www.apexbt.com



A PENEROLISMO DE DE

APENTE DE LEGIORE

AREX DO THE REAL PROPERTY OF THE PARTY OF TH

APETAL BIO ROLL TO THE STATE OF THE STATE OF

AFE BLOOM STATE OF THE STATE OF

A P E A pare de production de processor de la constante de la

ARE BIO

APE TOTAL LEGIO E POR L'ATTOCH